NEET-PG 2015 Practice Questions

Q: Transport of lipids from the intestine to other tissues is by -

Chylomicrons. ***Chylomicrons*** - **Chylomicrons** are the **largest lipoprotein particles** that transport **dietary (exogenous) lipids** from the **intestine** to peripheral tissues - They are synthesized in **intestinal enterocytes** after fat absorption and enter the bloodstream via the **lymphatic system (thoracic duct)** - They carry **triglycerides (85-95%), cholesterol, phospholipids, and fat-soluble vitamins** (A, D, E, K) - **Apolipoprotein B-48** is the characteristic structural protein of chylomicrons - After delivering triglycerides to tissues (via lipoprotein lipase), chylomicron remnants are taken up by the **liver** *LDL (Low-Density Lipoprotein)* - LDL transports **cholesterol from the liver to peripheral tissues** (not from intestine) - It carries **endogenous cholesterol**, not dietary lipids from the intestine - Often called "**bad cholesterol**" due to its role in atherosclerosis - Contains **Apolipoprotein B-100** *HDL (High-Density Lipoprotein)* - HDL performs **reverse cholesterol transport** - moving excess cholesterol from peripheral tissues **back to the liver** - It does **not transport lipids from the intestine** to tissues - Called "**good cholesterol**" for its protective cardiovascular role - Contains **Apolipoprotein A-I and A-II** *VLDL (Very-Low-Density Lipoprotein)* - VLDL is synthesized in the **liver** (not intestine) and transports **endogenous triglycerides** to peripheral tissues - It carries lipids **from the liver**, not from the intestine - VLDL is converted to IDL and then LDL after losing triglycerides - Contains **Apolipoprotein B-100**

Q: Which method is used to separate a mixture of lipids?

Chromatography. ***Chromatography*** - **Chromatography** (e.g., thin-layer chromatography, gas chromatography, high-performance liquid chromatography) is widely used to separate lipids based on differences in their **polarity**, **molecular weight**, or **solubility** in various solvents. - This method allows for the isolation and identification of different lipid classes and individual lipid species from a complex mixture. *Electrophoresis* - **Electrophoresis** separates molecules based on their **charge** and **size** in an electric field, making it more commonly used for proteins and nucleic acids. - Lipids are generally **uncharged** or have very low charge, which makes them poorly suited for separation by standard electrophoretic methods without modification. *Isoelectric focusing* - **Isoelectric focusing** is a type of electrophoresis that separates molecules based on their **isoelectric point (pI)**, which is the pH at which a molecule has no net charge. - This technique is primarily used for **proteins** and **peptides**, as lipids typically lack ionizable groups necessary for establishing a distinct pI. *PAGE* - **PAGE** (Polyacrylamide Gel Electrophoresis) is a common method used to separate **proteins** and **nucleic acids** based on their size and charge. - Lipids are **hydrophobic** and do not readily migrate through an aqueous polyacrylamide gel matrix, making PAGE unsuitable for their direct separation.

Q: Bile acids are synthesized from ?

Cholesterol. ***Cholesterol*** - **Bile acids** are derivatives of **cholesterol**, synthesized in the liver through a multi-step enzymatic pathway. - The conversion of cholesterol to bile acids is a primary mechanism for the excretion and transport of cholesterol from the body. *Heme* - **Heme** is a component of hemoglobin and myoglobin, primarily involved in oxygen transport and storage. - Its degradation product is **bilirubin**, which forms part of bile but is distinct from bile acids. *Ribulose* - **Ribulose** is a 5-carbon sugar, playing a key role in the **pentose phosphate pathway** and the **Calvin cycle** in photosynthesis. - It is not a precursor for bile acid synthesis. *Arachidonic acid* - **Arachidonic acid** is a polyunsaturated fatty acid that serves as a precursor for **eicosanoids** (prostaglandins, thromboxanes, and leukotrienes). - These molecules are involved in inflammation and immune responses but are unrelated to bile acid synthesis.

Q: Propranolol is most commonly prescribed as first-line therapy for which condition?

Thyrotoxicosis (excessive thyroid hormones). ***Thyrotoxicosis (excessive thyroid hormones)*** - **Propranolol** is commonly prescribed as **first-line symptomatic therapy** for **thyrotoxicosis** to manage symptoms such as **tachycardia, tremors, palpitations, and anxiety**. - It works by **blocking peripheral conversion of T4 to T3** and providing rapid **symptomatic relief** through beta-blockade. - While it does not treat the underlying thyroid disorder, it is the **immediate first-line agent** for symptom control while definitive treatment (antithyroid drugs, radioiodine, or surgery) is being arranged. - **Clinical pearl:** Propranolol is preferred over selective beta-blockers due to its additional effect on T4 to T3 conversion. *Hypertension (high blood pressure)* - **Propranolol** is **NOT a first-line agent** for hypertension in current guidelines (JNC 8, ESC/ESH). - First-line agents include **ACE inhibitors, ARBs, thiazide diuretics, and calcium channel blockers**. - Non-selective beta-blockers like propranolol are typically **third-line or later** due to unfavorable metabolic effects and side effect profile. - Selective beta-blockers (atenolol, metoprolol) may be used in specific hypertension scenarios, but propranolol is rarely first-line. *Atrioventricular (AV) block* - **Propranolol** is **absolutely contraindicated** in **AV block** as it further slows conduction through the AV node. - Beta-blockers can precipitate **complete heart block** in patients with pre-existing conduction abnormalities. *Cardiac arrest* - **Propranolol** is **contraindicated** in acute management of **cardiac arrest** as it reduces cardiac contractility and can worsen outcomes. - Cardiac arrest management involves **CPR, defibrillation, epinephrine, and amiodarone**.

Q: Permission from DCGI [Drug controller general, India] is needed before which phase of drug trial?

Phase 3. ***Phase 3*** - Permission from the **DCGI (Drug Controller General of India)** is mandatory before initiating **Phase 3** clinical trials as per **Schedule Y** of the Drugs and Cosmetics Rules. - Phase 3 trials involve **large-scale studies in Indian patients** to establish efficacy and safety in the target population, requiring explicit regulatory approval. - This is the critical regulatory checkpoint where DCGI evaluates the Phase 1 and 2 data before allowing widespread testing in Indian subjects. *Phase 1* - Phase 1 trials can be conducted after approval from the **Institutional Ethics Committee (IEC)** without requiring prior DCGI permission. - These trials in healthy volunteers focus on safety, pharmacokinetics, and dose-ranging studies. - DCGI is informed but explicit permission is not mandatory at this stage. *Phase 2* - Phase 2 trials also proceed with **IEC approval** and do not require prior DCGI permission. - These trials evaluate therapeutic efficacy and dose determination in a limited number of patients. - Results from Phase 2 are submitted to DCGI when seeking Phase 3 approval. *Phase 4* - Phase 4 trials are **post-marketing surveillance** studies conducted after drug approval. - These are conducted under the Post-Marketing Surveillance (PMS) framework. - While regulatory oversight exists, these are not pre-market trials requiring permission to initiate.

Q: Which of the following are CYP3A inhibitors?

Both a and c. ***Both a and c (Ritonavir and Verapamil)*** - **Ritonavir** is a **potent CYP3A4 inhibitor**, one of the strongest known, commonly used as a pharmacokinetic booster for other protease inhibitors to increase their bioavailability - **Verapamil** is a **calcium channel blocker** that acts as a **moderate CYP3A4 inhibitor**, leading to clinically significant drug interactions requiring dose adjustments - Both drugs have **clinically relevant and well-established** CYP3A4 inhibitory effects *Ritonavir alone* - While correct that Ritonavir is a potent CYP3A4 inhibitor, this option is incomplete as it excludes Verapamil - Ritonavir's inhibitory effect is so strong that it can increase plasma concentrations of co-administered CYP3A4 substrates by several-fold *Amiodarone* - Amiodarone is primarily a **potent inhibitor of CYP2C9, CYP2D6, and P-glycoprotein** - While it does have **weak to moderate CYP3A4 inhibitory activity**, this effect is **less clinically significant** compared to its effects on other CYP enzymes - In the context of clinically important CYP3A4 inhibitors, Ritonavir and Verapamil are more relevant examples *Verapamil alone* - While correct that Verapamil is a CYP3A4 inhibitor, this option is incomplete as it excludes Ritonavir - Verapamil can increase plasma concentrations of drugs like simvastatin, cyclosporine, and other CYP3A4 substrates

Q: Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?

ED50 of the drug corresponds to efficacy. ***ED50 of the drug corresponds to efficacy*** - **ED50** (median effective dose) is the dose at which 50% of individuals exhibit the specified effect; it quantifies **potency**, not efficacy. - **Efficacy** refers to the maximum effect a drug can produce, while potency refers to the amount of drug needed to produce an effect. *In a clinical setup, efficacy is more important than potency* - **Efficacy** determines the maximal therapeutic benefit a drug can achieve for a patient, making it crucial for clinical outcomes. - While **potency** influences the dose required, a highly potent drug that is not very efficacious may not be clinically useful. *Drugs that produce a similar pharmacological effect can have different levels of efficacy* - Two drugs might act on the same receptor but elicit different maximal responses, indicating varying **efficacy**. - For example, a **partial agonist** and **full agonist** interacting with the same receptor will have different efficacies. *In the log dose response curve, the height of the curve corresponds with efficacy* - The **maximal response** or plateau of the dose-response curve represents the **efficacy** of a drug. - A higher plateau on the curve indicates a drug with greater intrinsic activity achieving a larger effect.

Q: Fenoldopam is used in the management of?

Hypertensive emergencies. ***Hypertensive emergencies*** - **Fenoldopam** is a **dopamine D1 receptor agonist** that causes rapid, dose-dependent peripheral vasodilation and increased renal blood flow, making it suitable for acute blood pressure reduction during hypertensive emergencies. - Its **rapid onset** and short half-life allow for precise control of blood pressure, and its **benefit** in preserving or improving renal function is particularly beneficial in patients with renal impairment. *Congestive heart failure* - While fenoldopam can increase renal blood flow, it is not a primary treatment for **congestive heart failure (CHF)** and is not typically used for its management. - Other drug classes, such as **diuretics**, **ACE inhibitors**, and **beta-blockers**, are the mainstays of CHF treatment. *Migraine prophylaxis* - Fenoldopam has **no role** in the prevention or acute treatment of migraines. - **Beta-blockers**, **calcium channel blockers**, and certain **antidepressants** are commonly used for migraine prophylaxis. *Tachyarrhythmias* - Fenoldopam **does not have antiarrhythmic properties** and is not indicated for the treatment of tachyarrhythmias. - **Beta-blockers**, **calcium channel blockers**, and specific **antiarrhythmic drugs** are used to manage tachyarrhythmias.

Q: High volume of distribution is primarily determined by:

High lipid solubility. ***High lipid solubility***- Highly **lipid-soluble** drugs readily cross biological membranes and distribute extensively into tissues, including adipose tissue, CNS, and intracellular compartments, leading to a **high volume of distribution (Vd)** [1, 2].- This property allows the drug to move out of the bloodstream and into various body compartments, increasing the apparent volume in which the drug is dissolved [1].*High plasma protein binding*- **High plasma protein binding** generally **restricts** drug distribution to tissues because only the **unbound (free) fraction** can diffuse across capillary membranes into interstitial fluid and cells [1].- This typically leads to a **lower Vd**, as the drug is largely retained within the plasma compartment.*Elimination rate*- The **elimination rate** determines how quickly the drug is removed from the body, affecting the **duration of action** rather than the extent of distribution.- It influences drug concentration changes over time but does not directly determine the physical space (volume) into which the drug distributes.*Half-life of the drug*- The **half-life (t½)** is the time required for drug concentration to reduce by half, and it is **determined by** both Vd and clearance (t½ = 0.693 × Vd/CL).- Half-life is a **consequence** of Vd and clearance, not a primary determinant of how widely a drug distributes [3].

Q: Which of the following statements represents the most clinically significant aspect of drug metabolism?

Most common enzyme involved is CYP 3A4/5. ***Most common enzyme involved is Cyp 3A4/5*** - CYP3A4/5 is the **most abundant and clinically significant** cytochrome P450 enzyme, responsible for metabolizing approximately **50% of all clinically used drugs**. - Its widespread involvement means variations in its activity (due to **genetics, drug interactions, or disease**) have a major impact on drug efficacy and toxicity. *Glucuronidation is a phase II reaction* - While correct that glucuronidation is a **Phase II metabolic reaction**, this statement describes a biochemical classification rather than a clinically significant aspect compared to the involvement of CYP3A4/5. - Phase II reactions generally involve **conjugation** to increase water solubility and facilitate excretion, but they do not collectively account for as many drug interactions as CYP3A4/5 alone. *Reduction is a phase I reaction* - This statement is factually correct as **reduction** is indeed a **Phase I metabolic reaction**. - However, it represents a generic classification of a metabolic pathway and doesn't highlight the specific clinical importance or prevalence of a particular enzyme or reaction in drug metabolism. *Cytochrome P450 is involved in phase I reactions* - This is true; the **cytochrome P450 system** is the primary enzyme system for **Phase I metabolism**, which introduces or exposes polar groups to make drugs more reactive. - While fundamentally important, this statement is too broad; it does not specify the most clinically significant *aspect* or *enzyme* within the P450 system compared to directly identifying CYP3A4/5.

Question 1

Transport of lipids from the intestine to other tissues is by -

Accepted Answer

Chylomicrons

Answer

LDL

Answer

HDL

Answer

VLDL

Question 2

Which method is used to separate a mixture of lipids?

Accepted Answer

Chromatography

Answer

Electrophoresis

Answer

Isoelectric focusing

Answer

PAGE

Question 3

Bile acids are synthesized from ?

Accepted Answer

Cholesterol

Answer

Heme

Answer

Ribulose

Answer

Arachidonic acid

Question 4

Propranolol is most commonly prescribed as first-line therapy for which condition?

Accepted Answer

Thyrotoxicosis (excessive thyroid hormones)

Answer

Atrioventricular (AV) block

Answer

Hypertension (high blood pressure)

Answer

Cardiac arrest

Question 5

Permission from DCGI [Drug controller general, India] is needed before which phase of drug trial?

Accepted Answer

Phase 3

Answer

Phase 1

Answer

Phase 2

Answer

Phase 4

Question 6

Which of the following are CYP3A inhibitors?

Accepted Answer

Both a and c

Answer

Ritonavir

Answer

Amiodarone

Answer

Verapamil

Question 7

Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?

Accepted Answer

ED50 of the drug corresponds to efficacy

Answer

Drugs that produce a similar pharmacological effect can have different levels of efficacy

Answer

In a clinical setup, efficacy is more important than potency

Answer

In the log dose response curve, the height of the curve corresponds with efficacy

Question 8

Fenoldopam is used in the management of?

Accepted Answer

Hypertensive emergencies

Answer

Congestive heart failure

Answer

Migraine prophylaxis

Answer

Tachyarrhythmias

Question 9

High volume of distribution is primarily determined by:

Accepted Answer

High lipid solubility

Answer

High plasma protein binding

Answer

Elimination rate

Answer

Half-life of the drug

Question 10

Which of the following statements represents the most clinically significant aspect of drug metabolism?

Accepted Answer

Most common enzyme involved is CYP 3A4/5

Answer

Glucuronidation is a phase II reaction

Answer

Reduction is a phase I reaction

Answer

Cytochrome P450 is involved in phase I reactions

NEET-PG 2015

Biochemistry

Pharmacology